Vivani Medical, Inc.
VANI- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001266806
In the last 90 days, Vivani Medical, Inc. insiders filed 2 open-market purchases and 0 sales; 38 institutions reported holding it in 13F filings for Q2 2026, worth $6.47M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:18 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021! |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 13, 2025 | Mar 26, 2024 | – | – |
| Revenue | $0 | $0 | – | $475.0K | $12.0K |
| Cost of revenue | – | – | – | – | $130.0K |
| Gross profit | – | – | – | – | $130.0K |
| Operating expenses | $27.6M | $24.7M | $27.0M | $21.2M | $9.06M |
| Research and development | $18.1M | $15.7M | $17.0M | $14.2M | $2.37M |
| Selling, general and administrative | $9.43M | $8.93M | $10.0M | $7.07M | $6.32M |
| Operating income | -$27.6M | -$24.7M | -$27.0M | -$21.2M | -$8.93M |
| Net income | -$26.6M | -$23.5M | -$25.7M | -$13.9M | -$8.92M |
| EPS, basic | $-0.43 | $-0.43 | – | – | – |
| EPS, diluted | $-0.43 | $-0.43 | – | – | – |
| Weighted shares, basic | 62.4M | 55.0K | – | – | – |
| Weighted shares, diluted | 62.4M | 55.0K | – | – | – |
| Margins and growth | |||||
| Gross margin | – | – | – | – | 1083.3% |
| Operating margin | – | – | – | -4471.8% | -74441.7% |
| Net margin | – | – | – | -2924.0% | -74341.7% |
| Revenue growth, year over year | – | – | – | +3,858.3% | −25.0% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 13, 2025 | Mar 26, 2024 | – | – |
| Cash and equivalents | $16.2M | $18.4M | $20.7M | – | $69.6M |
| Total current assets | $17.9M | $20.4M | $23.1M | $47.5M | $70.5M |
| Property, plant and equipment | $2.88M | $1.69M | $1.73M | $1.18M | $117.0K |
| Total assets | $39.4M | $41.6M | $45.8M | $51.1M | $70.9M |
| Accounts payable | $1.03M | $817.0K | $542.0K | $1.18M | $519.0K |
| Total current liabilities | $6.60M | $5.99M | $5.72M | $6.82M | $2.46M |
| Total liabilities | $23.7M | $24.0M | $25.0M | $6.82M | $2.51M |
| Shareholders' equity | $15.7M | $17.6M | $20.8M | $44.3M | $68.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 13, 2025 | Mar 26, 2024 | – | – |
| Operating cash flow | -$24.3M | -$20.8M | -$23.7M | -$18.8M | -$9.19M |
| Capital expenditures | $1.17M | $556.0K | $887.0K | $338.0K | $14.0K |
| Free cash flow | -$25.5M | -$21.3M | -$24.6M | -$19.1M | -$9.20M |
| Depreciation and amortization | $424.0K | $400.0K | $357.0K | $381.0K | $70.0K |
| Stock-based compensation | $1.48M | $1.61M | $1.86M | $1.30M | $75.0K |
| Investing cash flow | -$1.17M | -$556.0K | -$887.0K | -$338.0K | -$14.0K |
| Financing cash flow | $23.3M | $19.1M | $133.0K | $63.4M | $75.6M |
| Net change in cash | -$2.12M | -$2.30M | -$24.4M | $44.3M | $66.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | – | 272.8% | 625.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 12, 2026 | 90.2M | +23.6% | SEC |
| Aug 13, 2026 | 90.2M | +52.3% | SEC |
| May 12, 2026 | 86.2M | +45.6% | SEC |
| Mar 25, 2026 | 84.6M | +42.9% | SEC |
| Nov 12, 2025 | 73.0M | +23.2% | SEC |
| Aug 12, 2025 | 59.2M | +7.2% | SEC |
| May 12, 2025 | 59.2M | +7.8% | SEC |
| Mar 28, 2025 | 59.2M | +7.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.